The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Need for myeloma trials comparing new agents with auto-SCT
At the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France, Inger Nijhof, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, discusses the need for clinical trials that compare treatments with and without autologous stem cell transplantation (auto-SCT). Dr Nijhof highlights that auto-SCT is performed due to concerns surrounding the risks of not carrying it out.
